This database contains 25 studies, archived under the term: "behavioral symptoms"
Click here to filter this large number of results.
Memory and communication support strategies in dementia: effect of a training program for informal caregivers
Liddle, Jacki,
Smith-Conway, Erin R.,
Baker, Rosemary,
Angwin, Anthony J.,
Gallois, Cindy,
Copland, David A.,
Pachana, Nancy A.,
Humphreys, Michael S.,
Byrne, Gerard J.,
Chenery, Helen J.
Background: People with dementia have a range of needs that are met by informal caregivers. A DVD-based training program was developed using research-based strategies for memory and communication in dementia. The effectiveness of the training on the caregiver experience and the well-being of the person with dementia was evaluated.; Methods: A pre-test/post-test controlled trial was […]
Serotonergic function and treatment of behavioral and psychological symptoms of frontotemporal dementia
Herrmann, Nathan,
Black, Sandra E.,
Chow, Tiffany,
Cappell, Jaclyn,
Tang-Wai, David F.,
Lanctôt, Krista L.
Objectives: The purposes of this study were first, to evaluate the effectiveness of citalopram in treating behavioral disturbances in frontotemporal dementia (FTD) subjects and second, to determine whether an association exists between serotonergic function, as determined by a neuroendocrine challenge, and treatment response.; Design: Single-dose citalopram (30 mg per os) challenge followed by a 6-week […]
Effects of yokukansan on behavioral and psychological symptoms of vascular dementia: an open-label trial
Nagata, Ken,
Yokoyama, Eriko,
Yamazaki, Takashi,
Takano, Daiki,
Maeda, Tetsuya,
Takahashi, Satoshi,
Terayama, Yasuo
Previous clinical trials suggest that the traditional Japanese medicine yokukansan has beneficial effects on the behavioral and psychological symptoms of dementia (BPSD). The present study was conducted to elucidate the efficacy of yokukansan on BPSD in patients with vascular dementia. Thirteen Japanese patients (9 men and 4 women) who were diagnosed as having vascular dementia […]
Treatment of behavioral and psychological symptoms of Alzheimer-type dementia with Yokukansan in clinical practice
Hayashi, Yoshihito,
Ishida, Yasushi,
Inoue, Teruhiko,
Udagawa, Mitsutaka,
Takeuchi, Kouzou,
Yoshimuta, Hirofumi,
Kiue, Kouichirou,
Ninomiya, Yoshimasa,
Kawano, Jiro,
Sameshima, Tetsuro,
Kawahara, Takashi,
Goto, Isamu,
Shudo, Kenji,
Kurayama, Shigeki,
Nakamura, Jungo,
Okahara, Kazunori,
Mitsuyama, Yoshio
The efficacy and safety of the kampo medicine Yokukansan (YKS, TJ-54) in the treatment of behavioral and psychological symptoms of dementia (BPSD) were investigated in patients with Alzheimer’s disease (AD) in an open-label study. This study included 26 patients who had been diagnosed as having AD and were not treated with donepezil hydrochloride. These patients […]
Serotonin transporter triallelic genotype and response to citalopram and risperidone in dementia with behavioral symptoms
Dombrovski, Alexandre Y.,
Mulsant, Benoit H.,
Ferrell, Robert E.,
Lotrich, Francis E.,
Rosen, Jules I.,
Wallace, Meredith,
Houck, Patricia R.,
Mazumdar, Sati,
Pollock, Bruce G.
The risk/benefit ratio of pharmacotherapy for behavioral symptoms of dementia is questionable: second-generation antipsychotics are poorly tolerated, and the efficacy of alternative treatments, for example, selective serotonin-reuptake inhibitors (SSRIs), is uncertain. Biomarkers of treatment response may improve this risk/benefit ratio. The length polymorphism of the serotonin transporter promoter gene (5-HTTLPR/SLC6A4) may moderate tolerability of SSRIs […]
Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression
Wang, Lucy Y.,
Shofer, Jane B.,
Rohde, Kirsten,
Hart, Kim L.,
Hoff, David J.,
McFall, Yun H.,
Raskind, Murray A.,
Peskind, Elaine R.
Objectives: Agitation/aggression in Alzheimer disease (AD) is a major cause of patient distress, caregiver burden, and institutionalization. Enhanced behavioral responsiveness to central nervous system norepinephrine (NE) release may contribute to the pathophysiology of agitation/aggression in AD. Prazosin, a nonsedating generic medication used for hypertension and benign prostatic hypertrophy, antagonizes NE effects at brain postsynaptic alpha-1 […]
Use of multisensory environments in the home for people with dementia
The purpose of this pilot study was to explore the feasibility and effectiveness of using multisensory environments (MSE) in the home of people with dementia. A qualitative research design was used, which included semi-structured interviews and self-rated caregiver observation checklists. Field notes and audio recorded interviews were transcribed for data analysis. Data were reduced and […]